Home > > Medical Devices > > Noninvasive Prenatal Testing Market Size, Share, Demand & Analysis (2035)
ID : CBI_3421 | Updated on : | Author : Yogesh K | Category : Medical Devices
Noninvasive Prenatal Testing Market size is estimated to reach over USD 19.36 Billion by 2035 from a value of USD 5.74 Billion in 2024 and is projected to grow by USD 6.41 Billion in 2025, growing at a CAGR of 11.69% from 2025 to 2035
The market for non-invasive prenatal testing (NIPT) comprises products and services for testing cell-free fetal DNA in maternal blood for chromosomal abnormalities during pregnancy. These products and services help identify and diagnose chromosomal abnormalities, including trisomy 21, 18, 13, and sex chromosome abnormalities, using next-generation sequencing and data analysis for accurate and timely prenatal screening and testing for healthcare and diagnostic centers.
The market for non-invasive prenatal testing is influenced by increasing maternal age and awareness of early genetic testing for chromosomal abnormalities. Advances in sequencing technology have improved the accuracy of NIPT and decreased testing times. Additionally, NIPT eliminates the need for invasive procedures and reduces miscarriage risk, making it more acceptable for healthcare and diagnostic centers.
With the use of AI, the machine learning and bioinformatics tools can be used for the analysis of cell-free fetal DNA sequencing with greater precision and speed. It helps to improve the detection of chromosomal abnormalities and decrease the false positives and false negative results. The AI system also analyzes the genomic data and clinical parameters for better risk assessment.
With the increase in the age of mothers in developed and emerging countries, the risk of chromosomal abnormalities, such as trisomy 21, trisomy 18, and trisomy 13, is also increasing. The mothers who have delayed their pregnancy at an older age are at a greater risk of genetic abnormalities. Therefore, the demand for non-invasive prenatal tests for the early screening of the fetus is increasing. The non-invasive prenatal tests, also known as NIPTs, can be used for the early screening of the fetus and the detection of abnormalities with the use of cell-free DNA analysis.
Therefore, rising maternal age is supporting growth of the noninvasive prenatal testing market.
The cost of non-invasive prenatal testing is also high compared to conventional screening tests. The use of advanced sequencing technology, laboratory facilities, and bioinformatics results in high costs for non-invasive prenatal testing. Lack of reimbursement policies in low and middle-income countries also limits the affordability of these tests.
Therefore, high costs are acting as a restraint for the growth of non-invasive prenatal testing.
The integration of AI and advanced bioinformatics tools in non-invasive prenatal testing is resulting in growth opportunities. The use of AI algorithms in non-invasive prenatal testing improves the interpretation of genomic data and results in high detection accuracy. Machine learning models help in the detection of rare chromosomal abnormalities using massive sequencing data.
Therefore, integration of artificial intelligence and bioinformatics platforms is expected to boost the noninvasive prenatal testing market in the future.
On the basis of gestation period, the noninvasive prenatal testing market is segmented into 0–12 weeks, 13–24 weeks, and 25–36 weeks.
Trends in the Gestation Period:
The 0–12 Weeks was responsible for the highest revenue share in 2024.
It is anticipated that the 13–24 Weeks will exhibit the highest compound annual growth rate (CAGR) during the forecast period.
On the basis of pregnancy risk, the market is divided into high & average risk and low risk.
Trends in the Pregnancy Risk:
High & average risk represented the highest revenue share in 2024.
Low risk is anticipated to exhibit the most rapid compound annual growth rate (CAGR) throughout the forecast period.
On the basis of method, the noninvasive prenatal testing market is divided into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests.
Trends in the Method:
Cell-free DNA in Maternal Plasma Tests accounted for the largest revenue share in the year 2024.
Biochemical Screening Tests is anticipated to register the fastest CAGR during the forecast period.
On the basis of technology, the market is divided into NGS, array technology, PCR, and others.
Trends in the Technology:
NGS represented the largest revenue share of 48.8% in 2024.
PCR is anticipated to register notable growth during the forecast period.

On the basis of product, the market is segmented into consumables & reagents and instruments.
Trends in the Product:
Consumables & Reagents accounted for the highest revenue share in 2024.
Instruments are projected to witness stable growth during the forecast period.
On the basis of application, the noninvasive prenatal testing market is segmented into trisomy, microdeletion syndrome, and other applications.
Trends in the Application:
Trisomy held the largest revenue share in 2024.
Microdeletion Syndrome is anticipated to exhibit faster growth during the forecast period.
On the basis of end-use, the market is divided into hospitals & clinics and diagnostic laboratories.
Trends in the End-Use:
Diagnostic Laboratories accounted for the largest revenue share in 2024.
Hospitals & Clinics are projected to register steady growth during the forecast period.
North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America are the regions of coverage.

In 2024, North America accounted for the highest market share at 40.37% and was valued at USD 2.32 Billion, and is expected to reach USD 7.82 Billion by 2035. In North America, the U.S. accounted for the highest market share of 88.1% during the base year of 2024. The growth is attributed to the increasing trends in maternal age and high awareness levels regarding early fetal chromosomal screening in the US and Canadian markets. Increasing pregnancy rates among women aged 35 years and above increases the likelihood of chromosomal abnormalities, thus strengthening the noninvasive prenatal testing (NIPT) solution based on cell-free DNA (cfDNA).

Asia Pacific market is expected to register the highest CAGR during the forecast period. This is due to the high birth rate and the rise in the number of people in the middle class, who are spending more on sophisticated prenatal care facilities. In this region, there is an increase in the availability of private maternity facilities and diagnostic laboratories.
Europe non-invasive prenatal tests market is driven by the established prenatal screening programs in Germany, France, and the UK. The public healthcare infrastructure is increasingly incorporating non-invasive prenatal tests in the care of pregnant women with high-risk pregnancies.
Latin America noninvasive prenatal testing market growth is fueled by expansion of private diagnostic laboratories in Brazil and Mexico. Rising maternal age and increasing focus on early fetal abnormality detection are increasing test growth.
Middle East and Africa noninvasive prenatal testing market is driven by healthcare infrastructure investment in the UAE and Saudi Arabia. Expansion of specialized diagnostic centers is improving access to prenatal genetic screening. South Africa is observing gradual adoption through private healthcare providers.
The non-invasive prenatal tests market is highly competitive, with established molecular diagnostics and genomic tests service providers offering advanced non-invasive prenatal tests in the domestic and international markets. Market participants are focusing on technological innovation in next-generation sequencing (NGS), portfolio expansion, strategic collaborations with hospitals and diagnostic laboratories, and geographic expansion to strengthen their market presence. Key participants in the market for Noninvasive Prenatal Testing include:
| Report Attributes | Report Details |
|---|---|
| Study Timeline | 2019-2035 |
| Market Size in 2035 (USD Trillion) | USD 19.36 Billion |
| CAGR (2025-2035) | 11.69% |
| By Gestation Period |
|
| By Pregnancy Risk |
|
| By Method |
|
| By Technology |
|
| By Product |
|
| By Application |
|
| By End Use |
|
| By Region |
|
| Key Players |
|
| Report Coverage |
|
The noninvasive prenatal testing market sizeis estimated to reach over USD 19.36 Billion by 2035 from a value of USD 5.74 Billion in 2024 and is projected to grow by USD 6.41 Billion in 2025, growing at a CAGR of 11.69% from 2025 to 2035.
The noninvasive prenatal testing report includes specific segmentation details for gestation period, pregnancy risk, method, technology, product, application, end-use, and regions.
In the noninvasive prenatal testing market, the low-risk pregnancy segment is anticipated to register the fastest growth during the forecast period, driven by expanding universal screening recommendations and increasing physician confidence in test accuracy.
The key participants in the Noninvasive Prenatal Testing marketare Illumina, Inc. (US), Natera, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), BGI Genomics Co., Ltd. (China), Laboratory Corporation of America Holdings (US), Quest Diagnostics Incorporated (US), Eurofins LifeCodexx GmbH (Germany), Berry Genomics Co., Ltd. (China), Myriad Genetics, Inc. (US), and Agilent Technologies, Inc. (US), among others.
The noninvasive prenatal testing market is shaped by key trends including increasing maternal age globally, expansion of first-trimester screening programs and rising adoption of cell-free DNA testing.